基准标记植入对胰腺癌立体定向放疗临床结局的影响
单中心回顾性研究纳入96例不可切除胰腺癌接受新辅助SBRT患者,按是否植入基准标记分为两组,比较局部复发、总生存及手术结局。中位随访20个月,局部复发率两组相似(aHR 0.6,95%CI 0.3-1.3,P=.59),总生存无差异(aHR 0.8,95%CI 0.3-1.9,P=.65),手术切缘与淋巴血管侵犯亦无差异。基准标记植入未对临床结局产生不良影响。
要点
- 基准标记植入组与未植入组局部复发率相似(aHR 0.6,95%CI 0.3-1.3,P=.59)。
- 两组总生存无显著差异(aHR 0.8,95%CI 0.3-1.9,P=.65)。
- 基准标记植入未增加急性胰腺炎等不良事件。
核心结论
- 基准标记植入未对局部晚期胰腺癌SBRT患者的局部复发、总生存及手术结局产生不良影响。
- 研究结果需前瞻性验证。
研究设计与样本
- 单中心回顾性研究,纳入96例接受新辅助SBRT的不可切除胰腺癌患者。
- 按是否植入基准标记分为两组:无标记组46例(47.9%),有标记组50例(52.1%)。
- 主要终点为局部复发,采用COX回归分析时间-事件终点。
主要发现
- 中位随访20个月,局部复发两组相似(aHR 0.6,95%CI 0.3-1.3,P=.59)。
- 总生存两组无差异(aHR 0.8,95%CI 0.3-1.9,P=.65)。
- SBRT后接受手术者,两组手术切缘(P=.40)和淋巴血管侵犯(P=.76)无差异。
- 基准标记植入后无患者发生急性胰腺炎。
关键数值与推荐
- 无标记组SBRT中位剂量36 Gy/5次,有标记组38 Gy/5次。
- 两组92.7%的患者在SBRT前接受化疗。
- 有标记组患者年龄更大且局部晚期比例更高。
临床怎么用
- 基准标记植入可用于胰腺癌SBRT的图像引导,未观察到对局部复发、生存或手术结局的负面影响。
- 需结合患者个体情况决定是否植入基准标记,尤其考虑年龄和分期。
局限性
- 回顾性单中心设计,样本量有限(96例),存在选择偏倚。
- 两组基线特征不平衡(年龄、局部晚期比例)。
- 结果需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Localized pancreatic cancer is commonly treated with stereotactic body radiation therapy (SBRT), which often requires the placement of fiducial markers. We compared the clinical outcomes of patients with and without fiducial markers. METHODS AND MATERIALS: We retrospectively collected data on patients with pancreatic cancer treated with neoadjuvant SBRT at a single institution. Patients were divided into 2 groups based on the placement of a fiducial marker. Local recurrence was the primary outcome. Time to event endpoints were analyzed using COX regression. RESULTS: We included 96 patients with unresectable pancreatic cancer: 46 patients (47.9%) did not have a fiducial marker, and 50 patients (52.1%) had a fiducial placed. Patients in the fiducial group were older and had more locally advanced pancreatic cancer compared with those who did not have a fiducial placed. Most patients in both groups (92.7%) received chemotherapy before SBRT treatment. SBRT was delivered to a median of 36 Gy over 5 fractions in the no-fiducial group, and 38 Gy over 5 fractions in the fiducial group. At a median follow-up of 20 months, local recurrence was similar irrespective of fiducial placement (adjusted hazard ratio [aHR] 0.6, 95% CI 0.3-1.3, P = .59). Furthermore, no difference in overall survival was noted between the 2 groups (aHR 0.8, 95% CI 0.3-1.9, P = .65). In patients who eventually underwent surgery post-SBRT, no difference in surgical margins (P = .40) or lymphovascular invasion (P = .76) was noted between the 2 groups. No patient developed acute pancreatitis after fiducial placement. CONCLUSIONS: Our data suggest that the use of fiducial markers does not negatively affect clinical outcomes in patients with localized pancreatic cancer. Prospective confirmation of our results is still needed.
引用
- Moningi S, Abi Jaoude J, Kouzy R, et al. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Adv Radiat Oncol. 2020. PMID: 33912734. doi:10.1016/j.adro.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。